Boyu Capital — 2019 Investments

1 investments dated 2019 · listed companies and verified rows first · show all

Antengeneantengene.comJan 2019 · $120M

Antengene is a biopharmaceutical company that develops therapies for cancer, with a pipeline focused on hematologic malignancies and solid tumors including Claudin 18.2, CD73, PD-L1/4-1BB bispecific, and CD24-targeting candidates.

BiotechHealthtech

Jay Mei(Founder)

Co-investorsDecheng Capital Qiming Venture Partners FountainVest Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.